BNGO
Bionano Genomics, Inc.1.5700
+0.0300+1.95%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
15.98MP/E (TTM)
-Basic EPS (TTM)
-12.77Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Q2 revenue dips, margins soar
Bionano Genomics reported Q2 2025 revenue of $6.7 million, down 13% from $7.8 million in Q2 2024 due to discontinued clinical services and fewer instrument sales, yet consumables and software rose 16% as routine OGM users drove growth. Gross margin surged to 52% from 33%, while operating expenses dropped 42% to $11.3 million, bolstering cash to $27.4 million. The strategy shift pays off. Company guides full-year revenue at $26-30 million and Q3 at $6.7-7.2 million, with cash lasting into Q1 2026 amid financing risks.
10-Q
Q2 FY2025 results
Bionano Genomics narrowed its Q2 FY2025 losses to $6.9M from $16.2M y/y, with revenue dipping 13% y/y to $6.7M on softer instrument sales but consumables up 28% y/y; gross margin expanded to 52% from 33% y/y, while operating expenses plunged 42% y/y to $11.3M, reflecting restructuring gains. For H1 FY2025, net loss shrank 79% y/y to $10.0M on $13.2M revenue (down 20% y/y), with diluted EPS improving to $(3.24) from $(47.50) on 3.1M weighted shares (derived). Cash burn eased to $6.3M from operations, ending with $3.6M cash, $12.9M short-term investments, and $11.0M restricted; $12.1M principal remains on 11% debentures due 2026, with $7.4M redemptions due in 2025. Extended HQ lease to 2030, but going concern doubts persist amid funding needs. Regulatory hurdles in diagnostics loom large.
8-K
Audit appointment and meeting approvals
Bionano Genomics bolstered its Audit Committee on June 10, 2025, by appointing Kristiina Vuori, M.D., Ph.D., enhancing oversight amid ongoing growth. At the June 11 annual meeting, with 47.82% turnout, shareholders elected R. Erik Holmlin and David Barker as Class I directors through 2028, approved executive pay advisory, ratified BDO USA as auditors, and greenlit 661,374 warrant shares for Nasdaq compliance. This strengthens governance while securing capital flexibility.
IPO
Website
Employees
Sector
Industry
AZTA
Azenta, Inc.
34.31-0.77
BDX
Becton, Dickinson and Company
196.39-3.70
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
NEO
NeoGenomics, Inc.
11.67-0.25
NTRA
Natera, Inc.
227.40-1.00
QGEN
Qiagen N.V.
45.01-0.43
TWST
Twist Bioscience Corporation
31.13+0.06
TXG
10x Genomics, Inc.
15.71-0.05
WGS
GeneDx Holdings Corp.
141.72-8.89